Combining the most common mutations in cell signaling genes such as NRAS, CBL, and JAK2, the prevalence of these aberrations was 55% in CMML patients with renal failure as compared to 38% among patients with normal kidney function (p = 0.056). The gene discussed is JAK2; the disease is chronic myelomonocytic leukemia.